ArticleCancer research and treatment2024
Predicted Cervical Cancer Prevention: Impact of National HPV Vaccination Program on Young Women in South Korea.
Article in Cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination.The Cochrane database of systematic reviews · 2025Pooled it
- Epidemiological characteristics of cervical cancer in Asian populations and risk factor inference based on Mendelian randomization.Medicine · 2026Article
- Diagnostic Performance of Post-Treatment F-18 FDG PET/CT for Detecting Recurrent Cervical Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Cervical cancer screening and HPV vaccination among assigned female at birth transgender and gender-diverse individuals in South Korea: findings from the KITE cohort.BMC public health · 2026Article
- Article
- Impact of switching from a quadrivalent to a nonavalent HPV vaccine on HPV infections and cervical cancer in Colombia: a mathematical modelling study.Lancet regional health. Americas · 2026Article
- Understanding barriers and facilitators to cervical cancer prevention among young Korean Women: A focus group interview study.PloS one · 2026Article
- Mathematical Assessment of the Roles of Vaccination and Pap Screening on the Burden of HPV and Related Cancers in Korea.Bulletin of mathematical biology · 2025Article
- Risk Factors of High-Grade CIN or Cervix Cancer in Young Women with Abnormal Pap Smear Results: Who Should Be Treated with LEEP (Loop Electrosurgical Excision Procedure)?Journal of clinical medicine · 2025Article
- Current Status of the National Cancer Screening Program in Korea: History, Achievements, and Future Directions.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeThis study aimed to evaluate the effectiveness of the national human papillomavirus (HPV) vaccination program of South Korea among its entire female population, particularly among younger age groups. MATERIALS AND
methodsWe first predicted the incidence of cervical cancer over the next 20 years (2021-2040) using the Nordpred package based on Møller's age-period-cohort model under several scenarios for the national HPV vaccination program. We calculated the potential impact fractions and proportional differences under the current national vaccination programs, and alternative scenarios using the no-vaccination assumption as a reference.
resultsWe estimated that the current national vaccination program would prevent 4.13% of cervical cancer cases and reduce the age-standardized incidence rate (ASR) by 8.79% in the overall population by 2036-2040. Under the alternative scenario of implementing the nine-valent vaccine, 5.13% of cervical cancer cases could be prevented and the ASR reduced by 10.93% during the same period. In another scenario, expanding the vaccination age to 9-17 years could prevent 10.19% of cervical cancer cases, with the ASR reduced by 18.57% during the same period. When restricted to ages < 40 years, the prevention effect was remarkably greater. We predict that the current national HPV program will reduce its incidence by more than 30% between 2036 and 2040 in women aged < 40 years.
conclusionThe effectiveness of the vaccination program in reducing the incidence of cervical cancer was confirmed, with a considerable impact anticipated in younger age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.